

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		08960557	
	Filing Date		1997-10-31	
	First Named Inventor	Eugenio A. Cefali		
	Art Unit	1611		
	Examiner Name	Channavajjla, Lakshmi Sarada		
	Attorney Docket Number	65,502-0013		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	08960557
Filing Date	1997-10-31
First Named Inventor	Eugenio A. Cefali
Art Unit	1611
Examiner Name	Channavajjala, Lakshmi Sarada
Attorney Docket Number	65,502-0013

1	DiPalma JR, Thayer WS. "Use of Niacin as a Drug, Annual Review of Nutrition," Vol. 11, pp. 169-187 (July 1991).	<input type="checkbox"/>
2	Grundy SM, et al., "Influence of Nicotinic Acid on Metabolism of Cholesterol and Triglycerides in Man," Journal of Lipid Research, Vol. 22, pp. 24-36 (1981).	<input type="checkbox"/>
3	Excerpt from 1997 Physicians' Desk Reference, pg. 2767	<input type="checkbox"/>
4	Upsher-Smith's Internet Advertisement at http://www.upsher-smith.com/sloniacin.html	<input type="checkbox"/>
5	Upsher-Smith's OTC Labels for 750mg, 500mg, and 250mg Slo-Niacin OTC products	<input type="checkbox"/>
6	Upsher-Smith's Package Insert used by Upsher-Smith with its 750mg, 500mg, and 250mg Slo-Niacin OTC Products	<input type="checkbox"/>
7	Gray et al. Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans. Annals of Internal Medicine, 121(3):252-258 (1994).	<input type="checkbox"/>
8	Wu et al. Promotion of extended-release niacin tablets at a Veterans Affairs medical center; Am. J. Hosp. Pharm., 47:2031-2034 (1990).	<input type="checkbox"/>
9	McKenney et al., A Comparison of the Efficacy and Toxic Effects of Sustained- vs. Immediate-Release Niacin in Hypercholesterolemic Patients. JAMA, 271(9):672-677 (1994).	<input type="checkbox"/>
10	Medical Science Bulletin, "The Toxicity of Niacin", http://pharminfo.com/pulbs/msb/niacin.html	<input type="checkbox"/>
11	Yin Ruixing, et al. "Comparison of Lipid Levels, Hyperlipidemia Prevalance and its Risk Factors Between Guangxi Hei Yi Zhuang and Han Populations," Archives of Medical Research, 2006, vol. 37, pp. 787-793	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	08960557
Filing Date	1997-10-31
First Named Inventor	Eugenio A. Cefali
Art Unit	1611
Examiner Name	Channavajjla, Lakshmi Sarada
Attorney Docket Number	65,502-0013

If you wish to add additional non-patent literature document citation information please click the Add button

Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.